Becton, Dickinson and Company $BDX Stock: AMI Asset Management Corp Lowers Stake

Key Points

• AMI Asset Management reduced its Becton, Dickinson and Company stake by 2.7% in the third quarter, selling 6,992 shares and retaining 250,265 shares worth approximately $44.8 million. Institutional investors and hedge funds collectively own 86.97% of BDX.
• BDX reported quarterly earnings of $3.23 per share, exceeding the $3.14 consensus estimate, while revenue reached $4.98 billion and rose 5.4% year over year. The company expects fiscal 2026 earnings of $12.62–$12.72 per share.
• The stock traded near its 52-week high at $193.77, while analysts maintained a consensus “Hold” rating with an average price target of $185.07. BDX also pays a $1.05 quarterly dividend, equivalent to a 2.2% yield.

AMI Asset Management Corp decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 2.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 250,265 shares of the medical instruments supplier's stock after selling 6,992 shares during the quarter. Becton, Dickinson and Company makes up approximately 2.6% of AMI Asset Management Corp's holdings, making the stock its 17th biggest holding. AMI Asset Management Corp owned 0.09% of Becton, Dickinson and Company worth $44,797,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Brown Lisle Cummings Inc. lifted its position in Becton, Dickinson and Company by 9.2% in the second quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier's stock worth $97,000 after purchasing an additional 54 shares during the period. Pension & Wealth Management Advisors Inc. increased its holdings in shares of Becton, Dickinson and Company by 12.3% in the third quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier's stock valued at $94,000 after buying an additional 56 shares in the last quarter. Elevation Point Wealth Partners LLC lifted its position in shares of Becton, Dickinson and Company by 3.7% during the 2nd quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier's stock valued at $256,000 after acquiring an additional 60 shares during the last quarter. Private Harbour Investment Management & Counsel LLC lifted its position in shares of Becton, Dickinson and Company by 1.1% during the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier's stock valued at $834,000 after acquiring an additional 62 shares during the last quarter. Finally, NorthRock Partners LLC boosted its stake in shares of Becton, Dickinson and Company by 2.0% during the 2nd quarter. NorthRock Partners LLC now owns 3,295 shares of the medical instruments supplier's stock worth $499,000 after acquiring an additional 65 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Up 1.6%

Becton, Dickinson and Company stock opened at $193.77 on Wednesday. The company has a 50 day moving average price of $184.51 and a 200 day moving average price of $164.26. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $195.99. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The firm has a market capitalization of $53.39 billion, a price-to-earnings ratio of 14.67, a P/E/G ratio of 12.86 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. Becton, Dickinson and Company's revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were paid a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio is currently 126.51%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president owned 19,720 shares in the company, valued at $3,717,022.80. This represents a 0.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares of the company's stock, valued at $20,380,155. This trade represents a 3.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 6,906 shares of company stock worth $1,265,855 in the last quarter. 0.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Wells Fargo & Company lifted their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an "equal weight" rating in a report on Friday, August 7th. UBS Group initiated coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a "buy" rating and a $190.00 target price on the stock. Piper Sandler upped their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Friday, August 7th. Wolfe Research started coverage on Becton, Dickinson and Company in a research report on Tuesday. They issued an "outperform" rating for the company. Finally, Citigroup reiterated a "buy" rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $185.07.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD's products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.